Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 1
2009 1
2010 1
2011 5
2012 2
2014 1
2015 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Novel human interleukin-15 agonists.
Zhu X, Marcus WD, Xu W, Lee HI, Han K, Egan JO, Yovandich JL, Rhode PR, Wong HC. Zhu X, et al. Among authors: yovandich jl. J Immunol. 2009 Sep 15;183(6):3598-607. doi: 10.4049/jimmunol.0901244. Epub 2009 Aug 26. J Immunol. 2009. PMID: 19710453 Free PMC article.
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.
Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, Dubois S, Bryant BR, Petrus M, Perera LP, Hsu J, Figg WD, Peer CJ, Shih JH, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA. Conlon KC, et al. Among authors: yovandich jl. Clin Cancer Res. 2019 Aug 15;25(16):4945-4954. doi: 10.1158/1078-0432.CCR-18-3468. Epub 2019 May 29. Clin Cancer Res. 2019. PMID: 31142503 Free PMC article. Clinical Trial.
Characterization of recombinant human IL-15 deamidation and its practical elimination through substitution of asparagine 77.
Nellis DF, Michiel DF, Jiang MS, Esposito D, Davis R, Jiang H, Korrell A, Knapp GC 4th, Lucernoni LE, Nelson RE, Pritt EM, Procter LV, Rogers M, Sumpter TL, Vyas VV, Waybright TJ, Yang X, Zheng AM, Yovandich JL, Gilly JA, Mitra G, Zhu J. Nellis DF, et al. Among authors: yovandich jl. Pharm Res. 2012 Mar;29(3):722-38. doi: 10.1007/s11095-011-0597-0. Epub 2011 Oct 19. Pharm Res. 2012. PMID: 22009587
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD Sr, Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA. Conlon KC, et al. Among authors: yovandich jl. J Clin Oncol. 2015 Jan 1;33(1):74-82. doi: 10.1200/JCO.2014.57.3329. Epub 2014 Nov 17. J Clin Oncol. 2015. PMID: 25403209 Free PMC article. Clinical Trial.
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.
Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP, Goldman CK, Bryant BR, Decker JM, Fleisher TA, Lane HC, Sneller MC, Kurlander RJ, Kleiner DE, Pletcher JM, Figg WD, Yovandich JL, Creekmore SP. Waldmann TA, et al. Among authors: yovandich jl. Blood. 2011 May 5;117(18):4787-95. doi: 10.1182/blood-2010-10-311456. Epub 2011 Mar 8. Blood. 2011. PMID: 21385847 Free PMC article.
Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization.
Vyas VV, Esposito D, Sumpter TL, Broadt TL, Hartley J, Knapp GC 4th, Cheng W, Jiang MS, Roach JM, Yang X, Giardina SL, Mitra G, Yovandich JL, Creekmore SP, Waldmann TA, Zhu J. Vyas VV, et al. Among authors: yovandich jl. Biotechnol Prog. 2012 Mar-Apr;28(2):497-507. doi: 10.1002/btpr.746. Epub 2011 Dec 9. Biotechnol Prog. 2012. PMID: 22162520 Free PMC article.
12 results